TolerogenixX Has Received EMA Orphan Drug Designation for MIC-Lx, Strengthening its Regulatory Pathway in Kidney Transplantation
TolerogenixX has received Orphan Drug Designation from the EMA for its kidney transplant therapy, MIC-Lx. This follows a previous PRIME designation, marking a significant step toward regulatory approval for a treatment designed to reduce reliance on systemic immunosuppression.
Why it matters
This development represents a potential shift in transplant medicine, aiming to improve long-term patient outcomes by minimizing the side effects of traditional anti-rejection drugs.
The Orphan Drug Designation follows the recent granting of EMA PRIME designation for MIC-Lx, marking a second key regulatory milestone and further strengthening the Company's pathway toward full regulatory approval.
Both designations recognize the significant unmet medical need in kidney transplantation addressed by MIC-Lx. Despite major advances in transplantation medicine, recipients today generally require lifelong systemic immunosuppressive therapy to prevent organ rejection. While effective, these therapies are associated with substantial long-term complications, including infections, malignancies, cardiovascular disease and chronic kidney damage, which continue to limit long-term patient outcomes.
Unlike conventional immunosuppressive therapies, MIC-Lx is designed to induce donor-specific immune tolerance before transplantation, enabling targeted protection of the transplanted organ while preserving the patient's overall immune competence. Based on TolerogenixX's proprietary Modified Immune Cell (MIC) technology, MIC-Lx aims to reduce dependence on lifelong systemic immunosuppression and improve graft survival and patients' long-term quality of life.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in